A M García Vicente1, B González García2, M Amo-Salas3, I García Carbonero4, J Cassinello Espinosa5, J L Gómez-Aldaraví Gutierrez6, L Suarez Hinojosa7, Á Soriano Castrejón2. 1. Nuclear Medicine Department, University General Hospital, C/Obispo Rafael Torija s/n, 13005, Ciudad Real, Spain. angarvice@yahoo.es. 2. Nuclear Medicine Department, University General Hospital, C/Obispo Rafael Torija s/n, 13005, Ciudad Real, Spain. 3. Departamento de Matemáticas, Universidad de Castilla La Mancha, Ciudad Real, Spain. 4. S. Oncología Médica, Complejo Hospitalario de Toledo, Toledo, Spain. 5. S. Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, Spain. 6. S. Oncología Médica, Hospital Universitario de Albacete, Albacete, Spain. 7. S. Oncología Médica, H. Manzanares, Ciudad Real, Spain.
Abstract
AIM: To establish the utility of baseline 18F-Fluorocholine (FCH) PET/CT and bone scintigraphy (BS) in the outcome prediction of patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with 223Ra. METHODS: Prospective, multicenter and non-randomized study (ChoPET-Rad study). FCH PET/CT and BS were performed before the initiation of 223Ra (basal FCH PET/CT and BS). Bone disease was classified attending the number of lesions in baseline BS and PET/CT. FCH PET/CT was semiquantitatively evaluated. Gleason score, baseline levels of prostate-specific antigen (PSA), alkaline phosphatase and lactate dehydrogenase were determined. Progression-free survival (PFS) and overall survival (OS) since the onset of 223Ra treatment was calculated. PFS was defined by PSA rising. Relations between clinical and imaging variables with PFS and OS were evaluated by Pearson, Mann-Whitney tests and Kapplan-Meier analysis. Univariate and multivariate Cox regression analysis was performed. RESULTS: Forty patients were evaluated. The median PFS and OS were of 3.0 ± 2.3 and 23.0 ± 4.2 months, respectively. 33 patients progressed and 13 died during the follow-up. The extension of the bone disease by FCH PET/CT (p = 0.011, χ2 = 10.63), BS (p = 0.044, χ2 = 8.04), SUVmax (p = 0.012) and average SUVmax (p = 0.014) were related to OS. No significant association was found for the PFS. ROC analysis revealed significant association of SUVmax, average SUVmax and basal PSA with OS. Only therapeutic failure was associated with OS in the multivariate analysis (HR = 3.6, p = 0.04). CONCLUSION: FCH PET/CT and BS had prognostic aim in the prediction of OS. None clinical or imaging variable was able to predict the PFS, probably due to the high rate of progressive disease.
AIM: To establish the utility of baseline 18F-Fluorocholine (FCH) PET/CT and bone scintigraphy (BS) in the outcome prediction of patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with 223Ra. METHODS: Prospective, multicenter and non-randomized study (ChoPET-Rad study). FCH PET/CT and BS were performed before the initiation of 223Ra (basal FCH PET/CT and BS). Bone disease was classified attending the number of lesions in baseline BS and PET/CT. FCH PET/CT was semiquantitatively evaluated. Gleason score, baseline levels of prostate-specific antigen (PSA), alkaline phosphatase and lactate dehydrogenase were determined. Progression-free survival (PFS) and overall survival (OS) since the onset of 223Ra treatment was calculated. PFS was defined by PSA rising. Relations between clinical and imaging variables with PFS and OS were evaluated by Pearson, Mann-Whitney tests and Kapplan-Meier analysis. Univariate and multivariate Cox regression analysis was performed. RESULTS: Forty patients were evaluated. The median PFS and OS were of 3.0 ± 2.3 and 23.0 ± 4.2 months, respectively. 33 patients progressed and 13 died during the follow-up. The extension of the bone disease by FCH PET/CT (p = 0.011, χ2 = 10.63), BS (p = 0.044, χ2 = 8.04), SUVmax (p = 0.012) and average SUVmax (p = 0.014) were related to OS. No significant association was found for the PFS. ROC analysis revealed significant association of SUVmax, average SUVmax and basal PSA with OS. Only therapeutic failure was associated with OS in the multivariate analysis (HR = 3.6, p = 0.04). CONCLUSION:FCH PET/CT and BS had prognostic aim in the prediction of OS. None clinical or imaging variable was able to predict the PFS, probably due to the high rate of progressive disease.
Authors: Iain Murray; Sarah J Chittenden; Ana M Denis-Bacelar; Cecilia Hindorf; Christopher C Parker; Sue Chua; Glenn D Flux Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-13 Impact factor: 9.236
Authors: Giampiero Giovacchini; Maria Picchio; Rita Garcia-Parra; Alberto Briganti; Firas Abdollah; Luigi Gianolli; Christian Schindler; Francesco Montorsi; Cristina Messa; Ferruccio Fazio Journal: J Nucl Med Date: 2014-01-09 Impact factor: 10.057
Authors: Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Alberto Bossi; Rob Bristow; Brett Carver; Daniel Castellano; Byung Ha Chung; Noel Clarke; Gedske Daugaard; Ian D Davis; Johann de Bono; Rodolfo Borges Dos Reis; Charles G Drake; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Celestia S Higano; Nicolas James; Philip Kantoff; Pirkko-Liisa Kellokumpu-Lehtinen; Raja B Khauli; Gero Kramer; Chris Logothetis; Fernando Maluf; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Vedang Murthy; William Oh; Piet Ost; Anwar R Padhani; Chris Parker; Colin C Pritchard; Mack Roach; Mark A Rubin; Charles Ryan; Fred Saad; Oliver Sartor; Howard Scher; Avishay Sella; Neal Shore; Matthew Smith; Howard Soule; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Ian Tannock; Bertrand Tombal; Riccardo Valdagni; Thomas Wiegel; Aurelius Omlin Journal: Eur Urol Date: 2017-06-24 Impact factor: 20.096
Authors: Laura Evangelista; Fabio Zattoni; Andrea Guttilla; Giorgio Saladini; Filiberto Zattoni; Patrick M Colletti; Domenico Rubello Journal: Clin Nucl Med Date: 2013-05 Impact factor: 7.794
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Matteo Bauckneht; Sara Elena Rebuzzi; Marta Ponzano; Roberto Borea; Alessio Signori; Viviana Frantellizzi; Elisa Lodi Rizzini; Manlio Mascia; Valentina Lavelli; Alberto Miceli; Maria Silvia De Feo; Antonio Rosario Pisani; Susanna Nuvoli; Vincenzo Tripoli; Alessio Giuseppe Morganti; Paolo Mammucci; Salvatore Caponnetto; Guglielmo Mantica; Angelo Domenico Di Nicola; Carlo Villano; Luca Cindolo; Silvia Morbelli; Gianmario Sambuceti; Stefano Fanti; Renato Patrizio Costa; Angela Spanu; Giuseppe Rubini; Fabio Monari; Giuseppe De Vincentis; Giuseppe Fornarini Journal: Cancers (Basel) Date: 2022-03-29 Impact factor: 6.639
Authors: Pierpaolo Alongi; Riccardo Laudicella; Helena Lanzafame; Andrea Farolfi; Paola Mapelli; Maria Picchio; Irene A Burger; Andrei Iagaru; Fabio Minutoli; Laura Evangelista Journal: Cancers (Basel) Date: 2022-03-31 Impact factor: 6.639